KEYMED BIO-B Surges Nearly 6% on Completion of Ouro Medicines Acquisition Deal and Receipt of $257 Million Initial Payment

Stock News06-12

Shares of KEYMED BIO-B (ASX: 02162) are rising close to 6%. At the time of writing, they are up 4.95%, trading at HK$58.3 with a turnover of HK$70.1441 million.

Recently, the company issued an announcement regarding the sale of its minority stake in Ouro Medicines. On June 5, 2026, the acquisition agreement disclosed in the announcement, involving the group's NewCo joint venture Ouro Medicines, has now been formally completed. The group has received an initial payment of $257 million.

Under the terms of the acquisition agreement, Gilead acquired all equity in Ouro Medicines for an upfront payment of $1.675 billion and potential milestone payments of up to $500 million. The group was informed that, according to an arrangement between Gilead Sciences and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT, formerly Galapagos), the two parties will share the upfront payment and the potential milestone payments of up to $500 million equally, subject to customary adjustments.

As a shareholder in Ouro Medicines, the group received approximately $257 million as its portion of the upfront payment and is entitled to potential milestone payments of up to approximately $70 million.

Furthermore, the exclusive license agreement entered into between the group and Ouro Medicines in November 2024 remains in effect. The potential milestone payments of up to $610 million and the tiered royalties on net sales are obligations to be fulfilled by Gilead and Lakefront.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192884477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 11:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192884477","market":"hk","top_or_hot":-1,"title":"KEYMED BIO-B Surges Nearly 6% on Completion of Ouro Medicines Acquisition Deal and Receipt of $257 Million Initial Payment","media":"Stock News","content":"<p>Shares of <b>KEYMED BIO-B</b> (<b>ASX: 02162</b>) are rising close to 6%. At the time of writing, they are up 4.95%, trading at HK$58.3 with a turnover of HK$70.1441 million.<br><br>\nRecently, the company issued an announcement regarding the sale of its minority stake in Ouro Medicines. On June 5, 2026, the acquisition agreement disclosed in the announcement, involving the group's NewCo joint venture Ouro Medicines, has now been formally completed. The group has received an initial payment of $257 million.<br><br>\nUnder the terms of the acquisition agreement, Gilead acquired all equity in Ouro Medicines for an upfront payment of $1.675 billion and potential milestone payments of up to $500 million. The group was informed that, according to an arrangement between Gilead Sciences and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT, formerly Galapagos), the two parties will share the upfront payment and the potential milestone payments of up to $500 million equally, subject to customary adjustments.<br><br>\nAs a shareholder in Ouro Medicines, the group received approximately $257 million as its portion of the upfront payment and is entitled to potential milestone payments of up to approximately $70 million.<br><br>\nFurthermore, the exclusive license agreement entered into between the group and Ouro Medicines in November 2024 remains in effect. The potential milestone payments of up to $610 million and the tiered royalties on net sales are obligations to be fulfilled by Gilead and Lakefront.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KEYMED BIO-B Surges Nearly 6% on Completion of Ouro Medicines Acquisition Deal and Receipt of $257 Million Initial Payment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKEYMED BIO-B Surges Nearly 6% on Completion of Ouro Medicines Acquisition Deal and Receipt of $257 Million Initial Payment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-12 11:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>KEYMED BIO-B</b> (<b>ASX: 02162</b>) are rising close to 6%. At the time of writing, they are up 4.95%, trading at HK$58.3 with a turnover of HK$70.1441 million.<br><br>\nRecently, the company issued an announcement regarding the sale of its minority stake in Ouro Medicines. On June 5, 2026, the acquisition agreement disclosed in the announcement, involving the group's NewCo joint venture Ouro Medicines, has now been formally completed. The group has received an initial payment of $257 million.<br><br>\nUnder the terms of the acquisition agreement, Gilead acquired all equity in Ouro Medicines for an upfront payment of $1.675 billion and potential milestone payments of up to $500 million. The group was informed that, according to an arrangement between Gilead Sciences and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT, formerly Galapagos), the two parties will share the upfront payment and the potential milestone payments of up to $500 million equally, subject to customary adjustments.<br><br>\nAs a shareholder in Ouro Medicines, the group received approximately $257 million as its portion of the upfront payment and is entitled to potential milestone payments of up to approximately $70 million.<br><br>\nFurthermore, the exclusive license agreement entered into between the group and Ouro Medicines in November 2024 remains in effect. The potential milestone payments of up to $610 million and the tiered royalties on net sales are obligations to be fulfilled by Gilead and Lakefront.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1192884477","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192884477","pubTimestamp":1781235027,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of KEYMED BIO-B (ASX: 02162) are rising close to 6%. At the time of writing, they are up 4.95%, trading at HK$58.3 with a turnover of HK$70.1441 million. Recently, the company issued an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","02162":"康诺亚-B","BK1574":"生物医药B类股","BK1587":"次新股","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念"},"translate_title":"完成Ouro Medicines收购交易并收到2.57亿美元首付款后，KEYMED BIO-B股价飙升近6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1,"VXUS":1},"content_text":"Shares of KEYMED BIO-B (ASX: 02162) are rising close to 6%. At the time of writing, they are up 4.95%, trading at HK$58.3 with a turnover of HK$70.1441 million.\nRecently, the company issued an announcement regarding the sale of its minority stake in Ouro Medicines. On June 5, 2026, the acquisition agreement disclosed in the announcement, involving the group's NewCo joint venture Ouro Medicines, has now been formally completed. The group has received an initial payment of $257 million.\nUnder the terms of the acquisition agreement, Gilead acquired all equity in Ouro Medicines for an upfront payment of $1.675 billion and potential milestone payments of up to $500 million. The group was informed that, according to an arrangement between Gilead Sciences and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT, formerly Galapagos), the two parties will share the upfront payment and the potential milestone payments of up to $500 million equally, subject to customary adjustments.\nAs a shareholder in Ouro Medicines, the group received approximately $257 million as its portion of the upfront payment and is entitled to potential milestone payments of up to approximately $70 million.\nFurthermore, the exclusive license agreement entered into between the group and Ouro Medicines in November 2024 remains in effect. The potential milestone payments of up to $610 million and the tiered royalties on net sales are obligations to be fulfilled by Gilead and Lakefront.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192884477","isCrawlerRequest":true}